Quality aspects related to data collection during follow up
| Epidemiologist/biostatistician | ||||
|---|---|---|---|---|
| Yes % (n=178) | No % (n=289) | Crude OR (95% CI) | Adjusted OR3-150 (95% CI) | |
| Date of starting clinical trial | ||||
| Yes | 70.2 | 43.3 | 3.1 (2.1, 4.6) | 2.1 (1.4, 3.3) |
| Date of ending clinical trial | ||||
| Yes | 68.0 | 40.5 | 3.1 (2.1, 4.6) | 2.2 (1.4, 3.3) |
| Justification of no blindness | ||||
| Yes/not applicable | 64.6 | 64.7 | 1.0 (0.7, 1.5) | 1.0 (0.7, 1.5) |
| Method to assess treatment compliance | ||||
| Yes | 45.5 | 35.3 | 1.6 (1.1, 2.3) | 1.2 (0.8, 1.9) |
| Assessment of intervention compliance | ||||
| Yes | 90.5 | 86.9 | 1.4 (0.8, 2.6) | 1.4 (0.7, 2.6) |
| Collection of side effects | ||||
| Yes | 78.1 | 73.4 | 1.3 (0.8, 2.0) | 1.2 (0.8, 1.9) |
| Masked assessment of outcome | ||||
| Yes | 51.7 | 51.6 | 1.0 (0.7, 1.5) | 0.9 (0.6, 1.3) |
| Outcome objectively assessed | ||||
| Yes | 92.1 | 83.0 | 2.4 (1.3, 4.4) | 2.4 (1.2, 4.6) |
| Existence of criteria to assess outcome | ||||
| Yes | 97.2 | 95.5 | 1.6 (0.6, 4.5) | 1.3 (0.4, 3.9) |
| Number of subjects who abandoned the study | ||||
| Yes | 93.8 | 97.2 | 0.4 (0.2, 1.1) | 0.5 (0.2, 1.3) |
↵3-150 Adjusted for number of participating centres, funding, and study sample size.